<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633177</url>
  </required_header>
  <id_info>
    <org_study_id>0308112690000</org_study_id>
    <secondary_id>R01DK088078</secondary_id>
    <nct_id>NCT01633177</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes</brief_title>
  <official_title>Diabetes Prevention in the Vitamin D and Omega-3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial&#xD;
      in 25,875 U.S. men and women investigating whether taking daily dietary supplements of&#xD;
      vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of&#xD;
      developing cancer, heart disease, and stroke in people who do not have a prior history of&#xD;
      these illnesses. This ancillary study is being conducted among nondiabetic participants in&#xD;
      VITAL and will examine whether vitamin D or fish oil prevent type 2 diabetes. Findings from&#xD;
      this proposed study conducted within the VITAL trial will clarify whether vitamin D and&#xD;
      omega-3 fatty acid supplementation reduces risk of type 2 diabetes and thus will inform&#xD;
      public health and clinical guidelines for diabetes prevention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emerging evidence suggests favorable effects of both vitamin D and marine omega-3 fatty acids&#xD;
      on glucose homeostasis. Optimal vitamin D intake is essential for insulin secretion and&#xD;
      action, and omega-3 fatty acids may reduce diabetes risk as a result of favorable effects on&#xD;
      insulin sensitivity, endothelial function, chronic inflammation, or other metabolic&#xD;
      abnormalities. Although the metabolic effects of vitamin D and omega-3 fatty acids show&#xD;
      considerable promise for the primary prevention of type 2 diabetes (T2D), there are no&#xD;
      completed, ongoing, or planned randomized clinical trials of vitamin D or omega-3 supplements&#xD;
      that include T2D as a primary outcome in a general population.&#xD;
&#xD;
      We thus propose to utilize an NIH-funded randomized trial (1 U01 CA138962) to test the&#xD;
      hypothesis that vitamin D and omega-3 supplementation will reduce the risk of T2D. We will&#xD;
      further assess whether and to what extent vitamin D or omega-3 supplementation will improve&#xD;
      insulin sensitivity and pancreatic beta-cell function in a subsample of the trial cohort. The&#xD;
      VITamin D and OmegA-3 TriaL (VITAL) is a randomized, double-blind, placebo-controlled trial&#xD;
      specifically designed to evaluate the benefits and risks of vitamin D3 (2,000 IU/day) and&#xD;
      marine omega-3 fatty acid (eicosapentaenoic acid [EPA] + docosahexaenoic acid [DHA], 1g/day)&#xD;
      supplements in the primary prevention of cancer and cardiovascular disease (CVD). The VITAL&#xD;
      trial will aim to enroll 20,000 men and women (aged ≥50 and ≥55 years, respectively). The&#xD;
      planned treatment duration is 5 years after a 1.5-year recruitment period. This diabetes&#xD;
      ancillary study aims to implement an inexpensive and efficient strategy to validate&#xD;
      self-reported incident T2D cases in the entire trial population and to collect pre- and&#xD;
      post-intervention measures of glucose, insulin, and hemoglobin A1c (HbA1c) in a subset of&#xD;
      participants. Two methods of diabetes case validation are proposed. First, we plan to collect&#xD;
      detailed information about diagnostic glucose testing and anti-diabetic medication use from&#xD;
      medical records and/or supplementary questionnaires completed by the participant's physician.&#xD;
      Second, to complement our diabetes ascertainment process, we will also plan to retrieve&#xD;
      additional data on diabetes diagnoses and hypoglycemic medications by linking the&#xD;
      participants with the Centers for Medicare and Medicaid Services (CMS) database. In addition&#xD;
      to evaluating whether the study interventions impact the onset of clinical diabetes, we&#xD;
      propose to collect pre- and post-intervention measures of glucose, insulin, and HbA1c in a&#xD;
      subset of the participants to reliably assess whether vitamin D or omega-3 supplementation&#xD;
      alters insulin and glucose homeostasis. We plan to recruit 1,000 participants without prior&#xD;
      clinical diabetes at the Clinical and Translational Science Center (CTSC) site at Brigham and&#xD;
      Women's Hospital. A standard 2-hour oral glucose tolerance test (OGTT) and HbA1c measurements&#xD;
      will be performed during the CTSC visits at baseline and at 2-year post-randomization.&#xD;
&#xD;
      Primary Aims:&#xD;
&#xD;
        1. To test whether vitamin D3 and/or EPA+DHA supplementation reduces the risk of T2D among&#xD;
           all initially non-diabetic participants in the VITAL trial.&#xD;
&#xD;
        2. To test whether vitamin D3 and/or EPA+DHA supplementation improves insulin sensitivity&#xD;
           and beta-cell function in a subset of 1,000 non-diabetic participants receiving OGTT at&#xD;
           baseline and 2-year post-randomization.&#xD;
&#xD;
      Secondary Aims:&#xD;
&#xD;
        1. To test whether vitamin D3 and/or EPA+DHA supplementation lowers HbA1c, fasting glucose&#xD;
           and insulin, as well as other surrogate indices of insulin sensitivity and beta-cell&#xD;
           function as determined by the homeostasis model assessment (HOMA-IR and HOMA-%B,&#xD;
           respectively) in our substudy.&#xD;
&#xD;
        2. To test whether vitamin D3 and EPA+DHA supplementation exerts synergistic or additive&#xD;
           effects on the risk of T2D among all initially non-diabetic participants in the VITAL&#xD;
           trial.&#xD;
&#xD;
        3. To test whether vitamin D3 and EPA+DHA supplementation exerts synergistic or additive&#xD;
           effects on insulin sensitivity and beta-cell function as assessed by OGTT in our&#xD;
           substudy.&#xD;
&#xD;
      For the above main effect estimates, we will further explore whether the effect of vitamin D3&#xD;
      or EPA+DHA supplementation varies by (1) age, (2) sex, (3) baseline intakes of these&#xD;
      nutrients, (4) baseline levels of 25(OH)D (for vitamin D3), (5) race/skin pigmentation (for&#xD;
      vitamin D3), (6) geographic region (for vitamin D3), and (7) BMI (for vitamin D3).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident type 2 diabetes</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OGTT index of insulin sensitivity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT index of beta-cell function</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c levels</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25875</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Vitamin D and Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D and Omega-3 placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo and Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo and Omega-3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day.</description>
    <arm_group_label>Vitamin D and Omega-3</arm_group_label>
    <arm_group_label>Vitamin D and Omega-3 placebo</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acid (fish oil)</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Vitamin D and Omega-3</arm_group_label>
    <arm_group_label>Vitamin D placebo and Omega-3</arm_group_label>
    <other_name>fish oil</other_name>
    <other_name>eicosapentaenoic acid</other_name>
    <other_name>docosahexaenoic acid</other_name>
    <other_name>EPA</other_name>
    <other_name>DHA</other_name>
    <other_name>Omacor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D3 placebo</description>
    <arm_group_label>Vitamin D placebo and Omega-3</arm_group_label>
    <arm_group_label>Vitamin D placebo and Omega-3 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D and Omega-3 placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo and Omega-3 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants in VITAL (NCT01169259) who have no history of diabetes mellitus at baseline&#xD;
        are eligible to participate in this ancillary study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yiqing Song, MD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Preventive Medicine, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Aruna Das Pradhan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Oral glucose tolerance test (OGTT)</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Beta-cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

